Additionally, as clinical trials are now being designed to move MET-directed therapy to frontline treatment for EGFR-mutated NSCLC patients, it is yet unknown if this will yield benefit for all patients, or if additional biomarker studies are needed to understand exactly which patients benefit from a combination approach. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.